EFTA00906003

From: "Alice Jacobs" • To: "Denise Marston" < Subject: IMDx Enters into Agreement with Biosearch Date: Wed, 16 Mar 2011 13:05:51 +0000 Attachments: -15MAR2011.pdf I wanted to update you with more news from IMDx. I hope that 2011 continues to be a great year for all of us. My best, Alice Biosearch Technologies and Intelligent Medical Devices, Inc. (IMDx) Finalize cGMP Oligo Supply and Licensing Agreements for Molecular Diagnostic Testing (IVD) Products. NOVATO, CA and CAMBRIDGE, MA (Monday, March 14, 2011) — Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, and IMDx (privately held), a developer and manufacturer of innovative, clinically impactful molecular test solutions, today announced that Biosearch has licensed access to the BHQ®, CAL Fluor® and Quasar® patents to IMDx. In addition, Biosearch will manufacture cGMP oligonucleotides for IMDx for use in human in-vitro diagnostics. -Biosearch Technologies is honored to have been chosen as IMDx's cGMP oligo provider," says Marc Beal, Director of Corporate Development at Biosearch Technologies. "IMDx's assays, powered by BHQ probing technologies,provides a potent combination for future diagnostic tests." "We are very pleased to be working with Biosearch. We believe BHQ probes are very effective, leading to highly differentiated products for many markets," says Alice Jacobs, MD, Chairman and CEO of IMDx. About Biosearch Technologies, Inc. Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 certified company, located in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR and other genomic-based applications. In addition to basic MI applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 3003009025), and as such, its contract manufacturing processes conform to all applicable GMP requirements per 21 CFR Part 820. Biosearch markets include pharmaceutical, in-vitro diagnostic, biotech, ag/bio, environmental and food testing, public health, and biodefense sectors. For additional information about Biosearch Technologies, Inc., contact or visit About Intelligent Medical Devices, Inc. Based in Cambridge, MA. IMDx is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of test solutions to meet clinical needs. For additional information about IMDx, contact or visit Media: EFTA00906003 Marc Beal. Director of Corporate Development Biosearch Technologies, Inc. Email: Website: Paige Ferraguto Director, Corporate Communications IntelligentMDx Cambrid e MA 02139 Email: Website: INN Alice A. Jacobs, M. Chairman 8 CEO Intelli Camb , MA 02139 Email: Visit us at The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential andfor privileged material. Any review. retransmission, dissemination or other use of. or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sends( and delete the material from all computers. EFTA00906004